Vesugen
Biologically active food supplement VESUGEN® is a peptide complex containing amino acids: lysine,
glutamic acid, aspartic acid, which has a normalizing effect on vascular tissue.
VESUGEN® is available in tablets or capsules with an active substance content of 0.100 mg.
Experimental studies have shown that VESUGEN® has a tissue-specific effect on the cells of the tissues
of the vascular wall, improves their trophism, and provides regulating action on the metabolic process-
es in them. It contributes to the normalization of functional and morphological changes in the vascular
wall, regulates cholesterol and lipoproteins blood content, reducing the risk of various vascular defects.
Thus, it is possible to extrapolate the efficiency of the use of VESUGEN® for the restoration of vascular
function in multiple diseases, including atherosclerosis.
Atherosclerosis and its consequences are one of the leading causes of disability among the population and
death in developed countries. Age-related changes in the vascular wall and hemodynamic disturbances
lead to decreased peripheral blood circulation, vascularization of organs and tissues, the development of
various components of oxygen deficiency, and trophic disorders in various organs and tissues (2, 3, 4, 6).
Drug treatment of atherosclerosis aims to normalize lipid metabolism, blood coagulation, and metabo-
lism in the vascular wall (1, 5).
Medicines that normalize cholesterol and β-lipoprotein levels:
- Drugs, which prevent the absorption of cholesterol in the intestine (cholestyramine, β-sitosterol, dio-
sponin, polysponine);
- Drugs, which affect cholesterol synthesis in the body (clofibrate, miscleron, regardin, cetamifen, nico-
tinic acid, vitamin PP);
- Drugs, which enhance the disintegration and excretion of cholesterol from the body (linetol, arachiden).
Means that improve microcirculation, normalize vascular permeability, reduce swelling of vascular tissues
and improve metabolic processes in the vascular wall:
- prodectin, dicynon, doxium, glivenol, escuzane, etc.
Clinical trials of VESUGEN® took place at the Medical Center of the Saint Petersburg Institute of Bio-
regulation and Gerontology of the Northwest Branch of the Russian Academy of Medical Sciences in
patients with atherosclerosis of various arteries in the period from November 2005 to February 2006.
Distribution of patients by nosological forms, sex and age Table 1
Diagnosis Age Men Women Total
(Years)
Primary Control Primary Control Primary
group group group group group
Atherosclerosis 54-77 8 15 7 10 15 25
Total: 40
CLINICAL CHARACTERISTICS OF PATIENTS
40 patients with atherosclerosis participated in the clinical trials, 25 of whom made up the primary
group (15 men, 10 women). In addition to conventional drugs, they were prescribed VESUGEN® orally
10-15 minutes before meals, 1-2 capsules 2-3 times a day for 10-15 days, depending on the severity of
the pathological process. 15 patients (8 men, 7 women) included in the control group were prescribed
only conventional drugs. The age of patients in both groups ranged from 54 to 77 years (Table 1).
Patients in both groups had different clinical manifestations of atherosclerosis, depending on vascular
lesions of different calibers: hypertension, coronary heart disease, cerebrovascular disorders with
impaired memory, concentration, and affective lability. All patients showed progressive dynamics of
disease development.
All patients previously received symptomatic and pathogenic therapy for specific clinical signs of
vascular pathology.
Для таблиц, дозировок и примечаний сверяйтесь с оригинальным PDF: при извлечении текста порядок колонок может измениться.
Из библиотеки Peptides. Авторство и содержание оригинала сохранены. Размещено с разрешения поставщика.